Treatment of childhood epilepsy with dipropylacetic acid (DPA)

Area of Science:

• Pediatric Neurology
• Epileptology
• Clinical Pharmacology

Background:

• Epilepsy is a common neurological disorder in children, often requiring long-term management.
• Therapy-resistant epilepsy presents a significant clinical challenge, necessitating exploration of alternative antiepileptic drugs.
• Dipropylacetate (DPA) is an antiepileptic medication with a distinct pharmacological profile.

Purpose of the Study:

• To evaluate the efficacy and safety of Dipropylacetate (DPA) in a pediatric epilepsy cohort.
• To determine the effectiveness of DPA across different epilepsy types and seizure classifications.
• To assess the impact of DPA on therapy-resistant epilepsy cases.

Main Methods:

• A cohort of 112 children (aged 1-20 years) with various epilepsy types received DPA treatment.
• Treatment duration averaged 19.8 months, with dosages ranging from 7 to 125 mg/kg/day.
• Patient outcomes were analyzed based on epilepsy classification, EEG patterns, and prior treatment responses.

Main Results:

• DPA demonstrated significantly better outcomes in primary generalized epilepsy compared to partial or secondary generalized epilepsy.
• High success rates were observed in absence seizures (92%) and primary generalized grand mal (87%).
• Efficacy in partial and secondary generalized epilepsy was contingent on 'centrencephalic' EEG patterns; focal epilepsy with pure focal EEG showed treatment failure and increased seizure frequency in some cases.

Conclusions:

• Dipropylacetate (DPA) is a valuable therapeutic option for specific pediatric epilepsy syndromes, particularly primary generalized epilepsy and absence seizures.
• The EEG pattern is a critical factor in predicting DPA response, with centrencephalic activity indicating a positive prognosis.
• Further research may elucidate DPA's role in managing refractory epilepsy and its specific mechanisms in different seizure types.